Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai
Betting on the biotech boom that’s now focusing considerable attention on China, WuXi AppTec has doubled down on its investment in one of its Shanghai complexes.
The global CRO is building a new R&D center next to an existing drug substance manufacturing site in the Jinshan district — one of five owned by WuXi’s STA subsidiary — with 30,000 square meters of lab space. Planning on a team of 500 scientists, WuXi is touting the center as a one-stop shop for biopharma partners to push APIs and advanced intermediates from preclinical stage through commercial launch.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.